- Trials with a EudraCT protocol (437)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
437 result(s) found for: Active lifestyle.
Displaying page 6 of 22.
EudraCT Number: 2012-003632-23 | Sponsor Protocol Number: NI-0501-04 | Start Date*: 2016-02-24 | |||||||||||
Sponsor Name:NovImmune SA | |||||||||||||
Full Title: A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... | |||||||||||||
Medical condition: Haemophagocytic lymphohistiocytosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) AT (Completed) CZ (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005496-17 | Sponsor Protocol Number: C16010 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed ... | |||||||||||||
Medical condition: Relapsed and/or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PT (Completed) AT (Completed) ES (Restarted) CZ (Completed) SE (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000255-13 | Sponsor Protocol Number: 11-019 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Me... | |||||||||||||
Medical condition: Prophylaxis of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LV (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) AT (Completed) DK (Completed) CZ (Completed) BG (Completed) IT (Completed) FI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004677-27 | Sponsor Protocol Number: ABX464-301 | Start Date*: 2019-09-16 | |||||||||||
Sponsor Name:Abivax | |||||||||||||
Full Title: Phase IIa randomized, double blind, placebo controlled, parallel group, multiple dose study on ABX464 in combination with methotrexate (MTX), in patients with moderate to severe active Rheumatoid A... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000241-74 | Sponsor Protocol Number: CNTO148AKS3001 | Start Date*: 2014-12-30 | |||||||||||
Sponsor Name:Janssen Biologics, BV | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing spondylitis (AS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004518-24 | Sponsor Protocol Number: I4V-MC-JAHV | Start Date*: 2019-04-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA) | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004805-34 | Sponsor Protocol Number: TDU13828-ACT13830 | Start Date*: 2015-04-02 | |||||||||||
Sponsor Name:Sanofi-aventis Research & Development | |||||||||||||
Full Title: A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety... | |||||||||||||
Medical condition: Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002955-85 | Sponsor Protocol Number: AVICCI001 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A feasibility study to assess the effects of AntiretroViral Intensification with Cenicriviroc for the management of HIV-associated Cognitive Impairment. The AVICCI study | |||||||||||||
Medical condition: Human Immunodeficiency Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003255-54 | Sponsor Protocol Number: RGB-03-104 | Start Date*: 2015-01-21 | |||||||||||
Sponsor Name:Gedeon Richter Plc | |||||||||||||
Full Title: A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006690-25 | Sponsor Protocol Number: OTCS-CE-301 | Start Date*: 2007-02-09 | |||||||||||
Sponsor Name:Novartis Consumer Health SA | |||||||||||||
Full Title: A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-being of Otrivin F2 ... | |||||||||||||
Medical condition: nasal congestion associated with the common cold | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004241-36 | Sponsor Protocol Number: ML42502 | Start Date*: 2021-03-23 | |||||||||||
Sponsor Name:Roche Farma S.A | |||||||||||||
Full Title: TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER. | |||||||||||||
Medical condition: EARLY BREAST CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002430-36 | Sponsor Protocol Number: AIO-HEP-0418-DEMAND | Start Date*: 2020-03-23 | |||||||||||
Sponsor Name:Klinikum der Ludwig-Maximilians-Universität München - [...] | |||||||||||||
Full Title: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progress... | |||||||||||||
Medical condition: Unresectable hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003185-12 | Sponsor Protocol Number: MK-3475-C93 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or... | |||||||||||||
Medical condition: First-line treatment of participants with dMMR advanced or recurrent EC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) NO (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005492-25 | Sponsor Protocol Number: PrEP-CS-003 | Start Date*: 2016-03-10 | |||||||||||
Sponsor Name:PrEP Biopharm Ltd. | |||||||||||||
Full Title: A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to investigate the duration of effect and evaluate further safety of PrEP-001 given prophylactically in heal... | |||||||||||||
Medical condition: Human Rhinovirus (HRV-16) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002134-74 | Sponsor Protocol Number: FLU-v004 | Start Date*: 2016-07-27 | |||||||||||
Sponsor Name:PepTcell Limited (trade name SEEK) | |||||||||||||
Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model | |||||||||||||
Medical condition: Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004296-77 | Sponsor Protocol Number: BTA585-003 | Start Date*: 2016-02-08 |
Sponsor Name:Biota Pharma Europe Limited | ||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral... | ||
Medical condition: Respiratory Syncytial Virus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004316-31 | Sponsor Protocol Number: FPP4-DE-401 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:Novartis Consumer Health S.A. | |||||||||||||
Full Title: A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions ... | |||||||||||||
Medical condition: Cold Sores caused by the herpes simplex virus (HSV) type 1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003946-99 | Sponsor Protocol Number: GETHI021 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI) | |||||||||||||
Full Title: A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood | |||||||||||||
Medical condition: Pediatric solid tumors presenting in adulthood | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003999-39 | Sponsor Protocol Number: C2501003 | Start Date*: 2020-08-17 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVER... | |||||||||||||
Medical condition: moderate to severe ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001045-39 | Sponsor Protocol Number: CT-P43_3.1 | Start Date*: 2020-11-12 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients with Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
